Factors associated with overall survival in FIGO 2009 stage IIIB cervical cancer in Botswana: univariate and multivariable analyses (n=187)
| Factor | N | Overall survival, UVA (HR (95% CI)) | P value | Overall survival, MVA (HR (95% CI)) | P value |
| Age (≥50 years) | 89 | 1.04 (0.71 to 1.53) | 0.85 | 1.23 (0.72 to 2.07) | 0.449 |
| HIV status (seropositive) | 118 | 1.14 (0.76 to 1.70) | 0.53 | 1.50 (0.88 to 2.57) | 0.138 |
| Weight (kg) (≥60)* | 81 | 0.69 (0.45 to 1.06) | 0.09 | ||
| Body mass index (kg/m2) (≤20)* | 42 | 1.13 (0.70 to 1.83) | 0.61 | ||
| Tumor histology (SCC vs non-SCC) | 165 | 0.99 (0.55 to 1.82) | 0.99 | ||
| History of tuberculosis (yes) | 17 | 0.84 (0.41 to 1.73) | 0.63 | ||
| CD4 count (<400)* | 62 | 1.52 (0.91 to 2.55) | 0.11 | ||
| Viral load (≥400)* | 11 | 1.24 (0.56 to 2.74) | 0.60 | ||
| Hemoglobin (g/dL) (<12)* | 139 | 1.35 (0.79 to 2.31) | 0.28 | 1.10 (0.61 to 1.96) | 0.759 |
| Creatinine (μmol/L) (>90)* | 31 | 1.45 (0.89 to 2.38) | 0.14 | ||
| KPS (40–80 vs 90–100)* | 54 | 1.33 (0.88 to 2.01) | 0.18 | 1.27 (0.81 to 1.96) | 0.294 |
| ART (yes) | 110 | 1.41 (0.51 to 3.87) | 0.51 | ||
| Treatment | |||||
| Total RT dose, EQD2 (≥80 Gy) | 65 | 0.52 (0.34 to 0.82) | 0.04 | 0.57 (0.35 to 0.92) | 0.023 |
| Brachytherapy (yes)* | 120 | 0.42 (0.28 to 0.62) | <0.01 | ||
| CRT (yes) | 90 | 0.57 (0.38 to 0.85) | 0.01 | 0.63 (0.39 to 0.99) | 0.045 |
| Treatment response (complete)*† | 80 | 0.45 (0.29 to 0.70) | <0.01 | ||
| Treatment year (2013–15 vs 2016–18) | 73 | 0.85 (0.57 to 1.27) | 0.43 | ||
| TTT (>3 months)*‡ | 90 | 1.16 (0.73 to 1.84) | 0.54 | ||
| RT course length (<7 weeks)* | 106 | 0.91 (0.62 to 1.35) | 0.642 |
*Data are incomplete due to missing individual patient data.
†Treatment response is defined as clinically apparent tumor regression on examination.
‡TTT is defined as time from pathological diagnosis to initiation of treatment.
ART, antiretroviral therapy; CRT, chemoradiation therapy; EQD2, radiobiological equivalent dose; FIGO, International Federation of Gynecology and Obstetrics; HIV, human immunodeficiency virus; KPS, Karnofsky Performance Score; MVA, multivariable analysis; RT, radiation therapy; SCC, squamous cell carcinoma; UVA, univariate multivariable analysis.